A METHOD TO IDENTIFY UPSTREAM REGULATORS OF ONCOGENES

Information

  • Research Project
  • 6724874
  • ApplicationId
    6724874
  • Core Project Number
    R43CA099113
  • Full Project Number
    5R43CA099113-02
  • Serial Number
    99113
  • FOA Number
    PAR-01-107
  • Sub Project Id
  • Project Start Date
    3/21/2003 - 21 years ago
  • Project End Date
    11/30/2005 - 18 years ago
  • Program Officer Name
    STRASBURGER, JENNIFER
  • Budget Start Date
    3/1/2004 - 20 years ago
  • Budget End Date
    11/30/2005 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/2/2004 - 20 years ago
Organizations

A METHOD TO IDENTIFY UPSTREAM REGULATORS OF ONCOGENES

[unreadable] DESCRIPTION (provided by applicant): [unreadable] [unreadable] A comprehensive understanding of all transduction partners, transcription factors, and their targets responsible for each type of primary tumor is lacking, despite intense effort. Furthermore, only a limited number of known "points of regulatory convergence," covering multiple cancer types, exists. Vaccinex has developed a highly efficient, proprietary technology for the identification of genes based on functional selection within a mammalian background. This method utilizes cDNA libraries inserted into the vaccinia virus (vv) genome and has been successfully applied to the isolation of novel tumor antigens. The ability to make libraries in vaccinia virus represents a major advance, since vaccinia virus is the only mammalian expression vector in which it is possible to construct a diverse and representative cDNA library whose elements can be efficiently recovered from the cytoplasm of infected cells. We propose to apply a variant of this functional gene selection technology to use known oncogenes and tumor cell markers as 'bait' to identify proteins that modulate their activity. [unreadable] [unreadable] This approach represents a refreshing, functional alternative to global transcript monitoring experiments performed with cDNA and oligonucleotide microarrays. Specifically, where microarray experiments monitor global transcriptional events related to cellular environment, our technique chooses a well-defined end point of transformation, either in the form of an up-regulated transcript or an over-abundant protein and proposes to uncover proteins that regulate these targets. Vaccinex technology, therefore, has the unique capability to functionally scan upstream in a transduction pathway. Moreover, the technique is designed to identify common points of regulation from overlapping pathways. Defining these regulatory mechanisms directly in the context of cancer is a critical step for generating more effective therapeutics. [unreadable] [unreadable]

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    216700
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:216700\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VACCINEX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ROCHESTER
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    14620
  • Organization District
    UNITED STATES